Abstract
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare malignancies where surgical resection is the primary curative treatment. However, high recurrence rates necessitate more effective strategies. This systematic review and meta-analysis evaluates the efficacy and safety of neoadjuvant therapy—treatment administered prior to surgery—in patients with GEP-NETs. Analyzing data from eight studies involving 457 patients, the results demonstrate that neoadjuvant therapy significantly improves overall survival (OS) and progression-free survival (PFS) without increasing postoperative complications.
Introduction
GEP-NETs represent a heterogeneous group of tumors arising from the digestive tract's endocrine system. While surgery is the gold standard for treatment, the risk of recurrence remains a significant challenge. In other gastrointestinal cancers, neoadjuvant therapy is used to downstage tumors and improve surgical outcomes. Due to the rarity of GEP-NETs, the clinical value of this approach has remained unclear. This study synthesizes current evidence to determine if neoadjuvant therapy offers a survival advantage for these patients.
Methods
A comprehensive search was conducted across PubMed, Embase, Cochrane Central Register of Controlled Trials, Web of Science, ClinicalTrials.gov, and China National Knowledge for studies published through June 30, 2020. The meta-analysis followed PRISMA and MOOSE guidelines.
- Data Extraction: For studies lacking explicit Hazard Ratios (HR), data points were extracted from Kaplan-Meier curves using Engauge Digitizer software.
- Statistical Analysis: Pooled HRs for OS and PFS were calculated using fixed-effects and random-effects models.
- Quality Assessment: The Newcastle-Ottawa scale was employed to ensure the inclusion of moderate-to-high quality observational studies.
Results
The final analysis included eight retrospective studies covering 457 patients. Neoadjuvant interventions primarily consisted of platinum-based chemotherapy, Peptide Receptor Radionuclide Therapy (PRRT), and chemoradiotherapy.
Survival Outcomes
The neoadjuvant therapy group showed a significant improvement in survival:
- Overall Survival: The pooled HR was 0.52 (95% CI: 0.41–0.66; P = 0.008), representing a 48% reduction in the risk of death.
- 5-Year OS: 65.25% in the neoadjuvant group vs. 46.79% in the surgery-only group (P < 0.001).
- Progression-Free Survival: 5-year PFS was significantly higher in the neoadjuvant group (30.64% vs. 14.46%, P = 0.04).
- Short-term Survival: 1-year OS was also improved (93.42% vs. 82.48%).
Pathological and Safety Findings
- Tumor Downsizing: Neoadjuvant therapy led to significantly smaller tumors at the time of surgery (mean 4.4 cm vs. 5.7 cm).
- Lymph Node Status: A higher proportion of patients achieved N0 status (no lymph node involvement) following neoadjuvant treatment (68.1% vs. 49.09%).
- Safety: There was no significant difference in postoperative complication rates between the groups (30% vs. 29.4%, P = 0.52), indicating that neoadjuvant therapy does not compromise surgical safety.
Discussion
The findings suggest that neoadjuvant therapy effectively "downstages" GEP-NETs, leading to smaller tumor sizes and improved lymph node status, which likely contributes to the observed survival benefits. Even in cases with liver metastases, a survival benefit was maintained (HR 0.62).
Conclusion and Future Directions
Neoadjuvant therapy provides a significant survival advantage for patients with operable GEP-NETs without increasing surgical risks. However, the reliance on retrospective data and the relatively small sample size are limitations. Future large-scale, multicenter randomized clinical trials are necessary to standardize treatment protocols and identify which patient subgroups benefit most from this approach.
Summary updated